Drugs
Conditions
News and resources
MIMS Supported ResourcesFirst licensed treatment for hidradenitis suppurativa
The licence for Humira (adalimumab) has been extended to include the treatment of active moderate to severe hidradenitis suppurativa (HS) in adults who have had an inadequate response to conventional HS therapy
To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content. View our subscription and registration options.